Endologix, Inc. (NASDAQ:ELGX)’s stock price traded up 10.4% during trading on Wednesday . The company traded as high as $2.55 and last traded at $2.54, 244,800 shares were traded during trading. An increase of 10% from the average session volume of 222,728 shares. The stock had previously closed at $2.30.

Several research analysts have recently commented on ELGX shares. Royal Bank of Canada set a $7.00 price target on Endologix and gave the stock a “hold” rating in a research report on Friday, August 9th. ValuEngine cut Endologix from a “buy” rating to a “hold” rating in a research note on Friday, November 1st. Finally, Zacks Investment Research downgraded Endologix from a “hold” rating to a “sell” rating in a report on Friday, November 8th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and one has issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $7.17.

The company has a market capitalization of $45.39 million, a PE ratio of -0.33 and a beta of 0.25. The company has a debt-to-equity ratio of 2.70, a current ratio of 2.22 and a quick ratio of 1.55. The stock’s 50 day simple moving average is $2.97 and its 200-day simple moving average is $5.22.

Endologix (NASDAQ:ELGX) last posted its quarterly earnings data on Wednesday, November 6th. The medical instruments supplier reported ($0.55) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.63) by $0.08. The business had revenue of $35.78 million during the quarter, compared to analyst estimates of $35.26 million. Endologix had a negative net margin of 58.24% and a negative return on equity of 99.62%. On average, equities analysts predict that Endologix, Inc. will post -2.69 earnings per share for the current year.

Institutional investors have recently added to or reduced their stakes in the business. Millennium Management LLC boosted its position in Endologix by 315.1% in the 3rd quarter. Millennium Management LLC now owns 101,945 shares of the medical instruments supplier’s stock valued at $404,000 after buying an additional 77,388 shares during the period. Public Employees Retirement System of Ohio acquired a new stake in shares of Endologix in the third quarter valued at $42,000. Russell Investments Group Ltd. acquired a new stake in shares of Endologix in the third quarter valued at $96,000. Walleye Trading Advisors LLC acquired a new stake in shares of Endologix in the second quarter valued at $158,000. Finally, Walleye Trading LLC purchased a new position in Endologix in the second quarter valued at $158,000. Institutional investors own 75.64% of the company’s stock.

About Endologix (NASDAQ:ELGX)

Endologix, Inc develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company offers minimally-invasive endovascular aneurysm repair (EVAR), including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the Ovation abdominal stent graft system.

See Also: What is the definition of market timing?

Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.